Banner Life Insurance Fit Review for Epilepsy and Seizure Disorders

Research Snapshot

Why Banner Life Qualified for This Study

Questions This Section Answers

• Is Banner Life a good choice for life insurance for epilepsy and seizure disorders?
• How many AI platforms named Banner Life for epilepsy life insurance, and how highly did it rank?

Banner Life qualified because it was named by five of the seven platforms during ranking discovery and finished with an average listed rank of 1.8 and a best rank of 1 ^[4]. That combination — broad mention plus high placement — is why it advanced to a full fit review rather than being dropped at the ranking stage.

Qualification is not the same as endorsement. The platforms that named Banner Life did so for different reasons. Some cited Banner's own published seizure underwriting criteria ^[9]. Others cited independent market commentary describing Banner and its Legal & General America affiliate as comparatively competitive for some epilepsy profiles ^[10]. One platform, deepseek, named Banner Life but reported that it could not locate any public Banner guideline specific to epilepsy or seizure disorders in the material it reviewed ^[13].

That divergence matters for a buyer. Banner Life's inclusion in this study reflects how often AI platforms surfaced it for this use case, not a verified claim that it is the best carrier for every seizure profile. The consensus index for Life Insurance for Epilepsy and Seizure Disorders shows how Banner Life compares with the other carriers that qualified.

The Product, Model, Plan, or Service Most Relevant to Life Insurance for Epilepsy and Seizure Disorders

Questions This Section Answers

• Which Banner Life plan should a buyer with epilepsy choose if they want long level-premium term coverage?
• Does Banner Life's BeyondTerm underwriting guide apply to its OPTerm term life product for seizure disorders?

The most relevant Banner Life offering for this use case is fully underwritten term life insurance, marketed as OPTerm, with BeyondTerm appearing as the underwriting pathway referenced in the seizure criteria ^[15]. OPTerm is renewable and convertible term coverage with level premiums during the selected term, and available terms include 10, 15, 20, 25, 30, 35, and 40 years ^[15]. Coverage amounts are reported from $100,000 to $10 million, with issue ages cited as 20 through 75 depending on term length ^[19].

The epilepsy-specific underwriting language that most platforms cited comes from Banner's BeyondTerm underwriting guide. That guide lists seizure/epilepsy as potentially acceptable when there have been no seizures for five years, no hospitalization for five years, the diagnosis occurred more than three months earlier with evaluation completed, and no medications are needed ^[20]. Banner's separate underwriting sweet-spots fact sheet adds that epilepsy with no seizures for at least five years may qualify for standard rates with complete investigation depending on cause, and that Standard Plus may be available for seizures within five years depending on type and assuming good control ^[23].

Two naming and scope problems should be flagged. First, platforms used "OPTerm" and "BeyondTerm" inconsistently, and one platform explicitly noted that product naming is inconsistent across sources and should be confirmed with Banner ^[26]. Second, the favorable "no medications needed" language comes from BeyondTerm materials, and it is not clear from the supplied evidence whether OPTerm underwriting applies identical criteria ^[21]. A buyer should confirm which product and which criteria set applies before applying.

What the AI Platforms Agreed About

Questions This Section Answers

• What do AI platforms agree on about Banner Life's seizure-free and medication requirements for epilepsy applicants?
• Is Banner Life's term life coverage convertible to permanent coverage without a new medical exam?

The clearest area of agreement is that Banner Life publishes specific, favorable epilepsy criteria tied to a long seizure-free period. Five platforms cited the same core thresholds: no seizures for five years, no hospitalization for five years, diagnosis more than three months earlier with evaluation completed, and no medications needed ^[27]. This is unusually specific for a life insurer, and it is the single strongest reason Banner Life appears in this study.

Platforms also agreed on the product structure. OPTerm is renewable and convertible term life insurance with level premiums during the term period and durations up to 40 years ^[32]. Multiple platforms reported that conversion to permanent coverage is available without new medical underwriting if conversion happens during the level premium period or before age 70, whichever comes first ^[35]. For policies issued at age 66 or older, the conversion window is limited to the first five years ^[39].

A third area of agreement is that Banner Life is not a guaranteed-issue or simplified-issue carrier for this condition. Platforms consistently described full medical underwriting as the expected path, with possible medical-record requests or a paramedical exam ^[41]. Several platforms reported that epilepsy may route an applicant out of accelerated, exam-free underwriting and into traditional review ^[45].

Where the AI Platforms Disagreed or Were Uncertain

Questions This Section Answers

• Do AI platforms disagree about whether Banner Life is a good or mixed fit for epilepsy life insurance?
• How does Banner Life treat applicants who still take anti-seizure medication but have been seizure-free for years?

Platform fit ratings split. Four platforms rated Banner Life a good fit (anthropic, google, kimi, perplexity), while three rated it mixed (openai, deepseek, grok). The disagreement is not about facts so much as about how much weight to give the narrow favorable criteria. Platforms rating it good emphasized the published seizure thresholds and competitive term pricing ^[48]. Platforms rating it mixed emphasized that the favorable criteria exclude medicated applicants and that no epilepsy-specific premium or approval data is public ^[51].

Medication is the sharpest unresolved question. The BeyondTerm criteria require no medications for the favorable scenario ^[51], but the underwriting sweet-spots fact sheet separately indicates Standard Plus may be available for seizures within five years depending on type and good control ^[55]. The supplied evidence does not clearly state how Banner treats an applicant who remains on antiseizure medication but has been seizure-free for several years ^[51]. One platform flagged this as a direct conflict between internal underwriting materials emphasizing Standard Plus availability and industry sources citing table ratings for recent tonic-clonic seizures ^[56].

Other open items: whether Banner requires ongoing neurologist follow-up or accepts general-practitioner management ^[54]; whether driving restrictions are a separate underwriting factor ^[58]; whether the 2021 postponement guidance for a recent known-cause grand-mal seizure is still current ^[60]; and whether BeyondTerm criteria apply to OPTerm ^[54]. One platform also reported that Banner's public website does not disclose epilepsy underwriting criteria at all, with high-risk references coming from independent sources ^[61].

Use-Case-Specific Features and Capabilities

Questions This Section Answers

• What term lengths and coverage amounts does Banner Life OPTerm offer for a buyer with epilepsy?
• Does Banner Life offer accelerated or no-exam underwriting for applicants with a seizure disorder?

Banner Life's most relevant capability for this use case is a published underwriting pathway that names epilepsy explicitly. The BeyondTerm guide's favorable criteria — five years seizure-free, five years without hospitalization, diagnosis more than three months earlier with evaluation completed, and no medications needed — are the clearest epilepsy-specific rules any platform cited for Banner ^[62]. The underwriting sweet-spots fact sheet adds that epilepsy with no seizures for at least five years may qualify for standard rates with complete investigation depending on cause ^[65].

Product flexibility is a second capability. OPTerm offers 10-, 15-, 20-, 25-, 30-, 35-, and 40-year level-premium terms with coverage from $100,000 to $10 million ^[67]. Conversion to permanent coverage without new medical underwriting is available during the level premium period or before age 70, whichever comes first ^[70]. That conversion feature matters for a buyer whose seizure control could change later.

Accelerated underwriting is a capability with a caveat. Banner states that its digital and accelerated processes can use electronic health records, attending physician statements, or recent laboratory results instead of a paramedical exam in some cases ^[73]. But multiple platforms reported that epilepsy and seizure disorders are typically excluded from exam-free programs, and that applicants with a seizure history may be routed to traditional underwriting with a medical exam ^[74]. One platform noted that Banner's APPcelerate program offers no-exam coverage up to $1 million for qualified applicants ages 20–50, but that eligibility depends on health history, prescriptions, and electronic health records ^[77].

Geographic availability is a practical constraint. Banner Life products are distributed in 49 states and the District of Columbia, with William Penn serving New York ^[79]. A New York applicant may receive a William Penn policy with potentially different product and underwriting details ^[79].

Pricing, Fees, Contracts, and Ongoing Costs

Questions This Section Answers

• How much does Banner Life cost per month for term life insurance, and is there an epilepsy-specific premium?
• What happens to Banner Life OPTerm premiums after the level term period ends?

Banner Life does not publish a reliable epilepsy-specific premium table. Every platform that addressed pricing rated its confidence low, and none produced a verified Banner quote for a seizure-disorder applicant ^[80]. Premium depends on age, sex, tobacco use, coverage amount, term length, state, seizure history, medications, medical records, and final underwriting class ^[80].

General Banner Life sample rates exist but are not epilepsy quotes. One independent review reported a 20-year, $500,000 policy averaging about $37 per month for women and $46 for men, described as the cheapest option reviewed ^[81]. Another reported a 35-year-old male preferred-plus at roughly $45 per month for a 20-year, $500,000 policy, and a 20-year-old female nonsmoker at $8.58 per month for a 10-year, $100,000 policy ^[81]. These are illustrative standard-risk figures and should not be treated as a Banner offer for an applicant with epilepsy.

On contract terms, OPTerm premiums are level during the selected term and guaranteed not to change for that duration ^[85]. After the level-premium period, coverage renews annually with increasing premiums, and the coverage amount may be reduced ^[80]. One platform reported post-level-term premiums increase annually until age 95 unless the policy is terminated ^[85]. A standard 30-day free-look period was reported by one platform ^[86]. Optional riders such as waiver of premium, child rider, and additional term rider carry additional fees, and the child rider is not available in Maryland or New York ^[87]. No epilepsy-specific fee was identified in the reviewed public materials ^[80].

Best Suited For

Questions This Section Answers

• Who is Banner Life best suited for among buyers with epilepsy or a seizure disorder?
• Is Banner Life a good fit for an applicant who has been seizure-free and off medication for five years?

Banner Life is best suited for applicants whose epilepsy history matches its published favorable criteria: no seizures for five years, no seizure-related hospitalization for five years, a completed evaluation, and no current seizure medication ^[88]. For that profile, Banner's own materials indicate standard or better rate-class acceptability, and independent sources describe preferred rates for applicants five or more years seizure- and medication-free ^[91].

It also suits buyers who want long level-premium term coverage. OPTerm's 10- to 40-year terms and $100,000 to $10 million coverage range give a stable applicant room to match coverage to a mortgage, income-replacement, or long-horizon need ^[94]. Buyers who value conversion flexibility without a new medical exam may also find the OPTerm-to-permanent conversion path useful ^[97].

A third fit is buyers willing to complete full medical underwriting in exchange for a definitive decision. Banner's underwriting is described as evaluating overall health rather than penalizing a single condition, which independent sources say can favor applicants with one well-managed health issue ^[99]. Most applicants receive a decision within two to four weeks after a complete application ^[101].

Probably Not Best Suited For

Questions This Section Answers

• Who should not choose Banner Life for life insurance with epilepsy or a seizure disorder?
• Is Banner Life a poor fit for an applicant with recent, frequent, or medication-controlled seizures?

Banner Life is probably not the best fit for applicants with recent, frequent, severe, or hospitalized seizures. The published favorable criteria are narrow, and the company's own 2021 underwriting update identifies a known-cause grand-mal seizure occurring less than three months after the first seizure as normally postponed ^[103]. One platform's field-guide citation describes postponement periods that differ by cause — known cause within three months of first seizure and unknown cause within six months — with a special exception for petit mal/absence seizures ^[104].

It is also a weaker fit for applicants who remain on antiseizure medication. The favorable BeyondTerm scenario requires no medications needed, and the supplied evidence does not clearly resolve how Banner treats medicated but well-controlled applicants ^[105]. One platform flagged that this requirement excludes many well-controlled applicants on stable medication ^[106].

Buyers seeking guaranteed-issue, simplified-issue, or no-exam coverage should look elsewhere. Banner's core offering is fully underwritten, and epilepsy is typically excluded from exam-free programs ^[108]. Buyers who want standalone whole life or indexed universal life as a primary product are also a poor fit: multiple platforms reported that Banner does not offer standalone whole life or indexed universal life, with permanent coverage available mainly through conversion ^[112]. One platform disagreed, stating Banner offers term, whole life, and indexed universal life ^[117], which is a conflict buyers should verify directly.

When Another Option May Be Better

Questions This Section Answers

• When is another carrier a better choice than Banner Life for a buyer with recent or medication-controlled seizures?
• What should a buyer do if Banner Life's preliminary underwriting response for epilepsy is unfavorable?

Another option may be better when the seizure profile falls outside Banner's narrow favorable criteria. One platform recommended using an independent broker to obtain informal underwriting opinions from multiple carriers when seizures are recent, medication-controlled, tonic-clonic, frequent, or associated with hospitalization ^[118]. The same platform identified Transamerica as potentially more flexible for tonic-clonic seizures, while noting Banner and Legal & General America as comparatively competitive for affordability and some absence-seizure histories ^[118].

Another option may be better when the buyer needs coverage Banner does not emphasize. Guaranteed-issue or simplified-issue final-expense coverage may be the practical path when conventional term insurance is unavailable, accepting lower limits and higher relative cost ^[118]. Workplace group life insurance is a separate or supplemental option if available, though portability and conversion rights should be verified ^[118]. Buyers who want permanent coverage from the start should look at carriers that offer standalone whole life or indexed universal life, since Banner's permanent coverage is mainly conversion-based ^[121].

Another option may be better when the buyer wants published, seizure-specific criteria before applying. One platform noted that many competing carriers publish explicit seizure/epilepsy underwriting criteria, making Banner's transparency for this exact niche unproven ^[123]. Independent sources also emphasize that a specialist broker's cross-carrier knowledge is valuable for epilepsy cases, suggesting Banner should be shopped comparatively rather than selected in isolation ^[124].

Questions to Verify Before Buying

Questions This Section Answers

• What should a buyer confirm with Banner Life about seizure type, medication, and records before applying?
• Which legal issuing company will appear on a Banner Life policy for a buyer in New York?

The supplied platform research produced a consistent verification list. Buyers should confirm, before submitting a formal application:

• Whether the current underwriter will consider this specific seizure type, date of last seizure, frequency, severity, and cause ^[126].
• Whether current antiseizure medication affects eligibility, rate class, postponement, or maximum coverage — and whether "no medications needed" is strictly enforced ^[128].
• Whether prior hospitalizations, emergency visits, injuries, nocturnal seizures, prolonged unconsciousness, or driving restrictions are material to the decision ^[126].
• What medical records, neurologist statement, EEG results, imaging, medication history, and seizure diary are required ^[126].
• Whether the application will receive accelerated underwriting or be routed to a paramedical exam and attending physician statement ^[131].
• What informal underwriting class and premium range is expected before a formal application ^[126].
• Which legal issuing company — Banner Life or William Penn — will appear on the policy in the buyer's state ^[134].
• The exact conversion period, conversion products, renewal rates, post-level-term premiums, and coverage-reduction provisions ^[126].
• Whether any exclusions or riders relate to epilepsy, seizures, hazardous activities, or driving ^[126].
• Whether competing informal offers should be obtained before completing a formal application that could create an underwriting record ^[137].

Final AI Consensus Verdict

Banner Life is a mixed fit for life insurance with epilepsy or a seizure disorder. Five of seven platforms named it during ranking discovery, and it placed in the top three overall, but platform fit ratings split four "good" to three "mixed." The strongest reason to consider Banner Life is its unusually specific published underwriting criteria: no seizures for five years, no hospitalization for five years, completed evaluation, and no medications needed, with Standard Plus potentially available for well-controlled seizures within five years ^[138]. The main limitation is that those favorable criteria are narrow, advisor-only, and non-exhaustive, and no epilepsy-specific premium or approval data is public ^[138].

For a buyer who has been seizure-free and medication-free for five or more years, Banner Life is worth considering first or alongside competitors. For a buyer with recent, frequent, medicated, or hospitalized seizures, Banner should not be treated as the clear best choice; a broker-led comparison with carriers that have different seizure underwriting rules is more appropriate ^[144]. Platform agreement on Banner's published criteria does not prove product quality or guarantee an underwriting outcome.

How This Review Was Produced

This review was generated from seven AI platform responses collected for the topic "Best Life Insurance for Epilepsy and Seizure Disorders," using the run research date of 2026-09-22. Banner Life qualified for a full fit review because it was named by five of the seven platforms during ranking discovery and met the minimum-mention threshold. Each platform's fit assessment, use-case findings, pricing notes, limitations, and verification questions were reviewed and consolidated. Platform fit ratings were tallied as reported: four good (anthropic, google, kimi, perplexity) and three mixed (openai, deepseek, grok). All factual claims are cited to the supplied citation IDs, and company-owned sources are distinguished from independent sources throughout.

Methodology Limitations

Several limitations apply. Platform-reported research dates differ from the authoritative run date: deepseek reported 2026-06-01 while the other six platforms reported 2026-09-22, so deepseek's findings may be less current. Deepseek also ran without search enabled, so its claims are platform-reported rather than retrieved. All citations are platform-reported evidence and were not independently verified by the writer stage, and the supplied URLs were not independently validated.

The deterministic identity audit noted that official-site retrieval failed for one or more mentions, that one or more fetched domains were not corroborated by brand-name or site-identity metadata, and that company-name variants were collapsed onto one canonical brand before qualification. The single retrieved official-page excerpt was marked retrieved-not-verified. Product naming is inconsistent across sources (OPTerm vs. BeyondTerm), and the supplied evidence does not resolve whether BeyondTerm epilepsy criteria apply to OPTerm. Banner's detailed epilepsy criteria come from an advisor-only guide marked not for public distribution, and a 2021 underwriting update's current applicability is unclear. No epilepsy-specific premium table, approval-rate data, or exclusion language was verified. Platform agreement on Banner's published criteria does not establish product quality or a guaranteed underwriting outcome.